Researchers used computer modeling to examine the interactions of aloe vera compounds with the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), which are associated with Alzheimer's disease.[1][2] Beta-sitosterol showed a strong binding affinity of −8.6 kcal/mol to AChE and −8.7 kcal/mol to BChE, which is better than other compounds such as succinic acid.[1][2] This compound demonstrated stability and strong binding to both enzymes.[1] ADMET analysis showed a favorable profile of beta-sitosterol with good absorption and low toxicity.[1][2] A study published in Current Pharmaceutical Analysis identifies beta-sitosterol as a promising candidate for a dual enzyme inhibitor in Alzheimer's disease.[1][2] The results provide a basis for further experimental validation and clinical trials.[1]